Roche Mulls Xenical Rx-To-OTC Switch To Stop Slimming Prescription Sales
This article was originally published in The Tan Sheet
Executive Summary
Roche's slumping anti-obesity prescription drug sales and a vacuum of high-profile products in the over-the-counter drug and dietary supplement weight-loss markets could persuade the firm to pursue an Rx-to-OTC switch for Xenical
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning